Clinical Trial

Effect Of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors on Body Mass Index After 3 Months of Use in Diabetic Patients

Completed Phase 1
View on ClinicalTrials.gov →
Summary
Total of 360 participants were enrolled and prescribed oral 200 mg SGLT-2 tablet. All participants were followed-up for about three months. Body mass index was measured before and after three months and mean change in BMI was assessed.
Trial Details
NCT Number NCT07367555
Lead Sponsor Ariba Shafiq
Conditions Diabete Mellitus
Enrollment 360 participants
Start Date 2024-10-01
Primary Completion 2025-03-31 (estimated)
Study Completion 2025-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-26